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Abstract
A tremendous amount of scientific evidence regarding the physiology and physiopathology of high
blood pressure combined with a sophisticated therapeutic arsenal is at the disposal of the medical
community to counteract the overall public health burden of hypertension. Ample evidence has
also been gathered from a multitude of large-scale randomized trials indicating the beneficial effects
of current treatment strategies in terms of reduced hypertension-related morbidity and mortality.
In spite of these impressive advances and, deeply disappointingly from a public health perspective,
the real picture of hypertension management is overshadowed by widespread diagnostic inaccuracies
(underdiagnosis, overdiagnosis) as well as by treatment failures generated by undertreatment,
overtreatment, and misuse of medications.
The scientific, medical and patient communities as well as decision-makers worldwide are striving
for greatest possible health gains from available resources.
A seemingly well-crystallised reasoning is that comprehensive strategic approaches must not only
target hypertension as a pathological entity, but rather, take into account the wider environment
in which hypertension is a major risk factor for cardiovascular disease carrying a great deal of our
inheritance, and its interplay in the constellation of other, well-known, modifiable risk factors, i.e.,
attention is to be switched from one's "blood pressure level" to one's absolute cardiovascular risk
and its determinants. Likewise, a risk/benefit assessment in each individual case is required in order
to achieve best possible results.
Nevertheless, it is of paramount importance to insure generalizability of ABPM use in clinical
practice with the aim of improving the accuracy of a first diagnosis for both individual treatment
and clinical research purposes. Widespread adoption of the method requires quick adjustment of
current guidelines, development of appropriate technology infrastructure and training of staff (i.e.,
education, decision support, and information systems for practitioners and patients). Progress can
be achieved in a few years, or in the next 25 years.
Introduction
During the past decades, hypertension, denoting abnormal
elevation of blood pressure, has commonly been assigned
a distinct disease quality. The majority of the medical com-
munity as well as renowned medical textbooks have
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considered it a pathological entity requiring diagnostic
and appropriate treatment in most individuals having it.
Inherent in the 100-year old approach of discriminating
between normal and abnormal blood pressure is, how-
ever, an arbitrary threshold established currently at 140/
90 mmHg for mild hypertension and two higher cut-off
values to define moderate and severe hypertension. This
classification, still maintained as such by the ESH [1] and
WHO [2] guidelines, has been in use for many decades
both for management of hypertension in individual sub-
jects and for defining patient population samples targeted
for testing of new antihypertensive drugs.
It is common knowledge, however, that up to 95% of
hypertensive individuals have high blood pressure of
unknown etiology denoted essential hypertension. The
majority of these have mild hypertension while some
10% of them have either moderate or severe degrees of
hypertension.
Classically, the diagnosis of essential hypertension has
been regarded as pretty straightforward, as long as a sec-
ondary hypertension could be ruled out with confidence.
While this latter entity can, on justifiable grounds, be con-
sidered a disease, essential hypertension is a quantitative
expression of the fluctuations of a biologic variable – the
blood pressure – that should be considered a major risk
factor for cardiovascular disease at best, rather than a dis-
ease by itself.
Nevertheless, with increasing awareness that the trade-off
between normality and abnormality on a blood pressure
curve is confounded by large diurnal and random varia-
tion of the blood pressure variable, by individual factors
such as age, sex, race as well as by a great number of poten-
tial errors occurring during blood pressure measurement
per se, the medical and scientific community are desper-
ately in search for approaches to increase the accuracy of
diagnosis and management of hypertension and to shift
the weight of decision making from the current "BP-
value"-focused attitude to the appraisal of any patient's
absolute risk, rather than his/her individual risks (i.e.,
high blood pressure, hypercholesterolemia, smoking,
overweight, etc.) [3-5].
The driver behind the need for radical change is at least
two fold:
1. The widespread awareness that the hypertension-
related risk – in terms of cardiovascular complications,
stroke and renal disease – rises in relation to increases of
both systolic and diastolic blood pressure [6-13].
2. The hypertension diagnosis currently implies not only
exclusion of secondary causes of hypertension but as well,
careful consideration is to be given to differentiating enti-
ties like: white coat hypertension [14-17], white coat effect
[18,19], masked hypertension [20-22] and prehypertension,
from the genuine, sustained hypertension [23].
The clustering of these entities around the current diag-
nostic cut-off point (140/90 mmHg) generates a BP uncer-
tainty range (130/85-160/95 mmHg) reflecting a
universally widespread inaccuracy of a first diagnosis
based on office BP measurements and a consequent inap-
propriate long-term management of the subjects assessed.
Blood pressure measurement as a diagnostic 
test – a clinical epidemiology perspective
Commonly, variation in clinical medicine may be due to
fluctuations of biologic variables or the presence or
absence of disease as well as the nature of that disease and
its severity; it may also be due to differences in measure-
ment technique, errors in measurement, observer bias,
and to a great extent to random variation.
The blood pressure variable happens to be a typical exam-
ple that displays all the aforementioned variation param-
eters. An attempt to understand this variation through
gaining insight in relative simple epidemiology and statis-
tical concepts and then acting on the basis of the new
acquired knowledge, might be the key to account for the
blood pressure overall variability, to accurately interpret
the prognostic significance of any blood pressure values
and confidently manage pharmacological therapy in all
hypertensive patients.
In the general population blood pressure values follow a
smooth bell-shaped distribution as displayed in Fig. 1 for
the SBP and in Fig. 2 for the DBP. The two histograms
attempt to account for the known general prevalence of
hypertension worldwide [24], with higher figures for the
SBP as compared with DBP due to their divergent pattern
at higher ages (and both sexes) [25]. The black bars high-
light the frequency distribution of the blood pressure val-
ues considered abnormal (according to the arbitrary
threshold of 140/90 mmHg).
The distribution of SBP is slightly skewed to the right due
to the high proportion of people with BP values in the
range 140-160 mmHg [26].
Certainly, both systolic and diastolic blood pressure
belong to one and the same, simplified, theoretical nor-
mal distribution (Fig. 3) assumed to describe the underly-
ing population from which relevant data might be derived
[27,28]. Fig. 3 suggests that all normal blood pressureCurrent Controlled Trials in Cardiovascular Medicine 2005, 6:5 http://cvm.controlled-trials.com/content/6/1/5
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Normal distribution of SBP values in the general population Figure 1
Normal distribution of SBP values in the general population.
Normal distribution of DBP values in the general population Figure 2
Normal distribution of DBP values in the general population.
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values measured in the population are comprised by the
interval given by the mean ± two standard deviations (M
± 2SD).
Assuming that the commonly used office blood pressure
measurement was an ideal test (a "gold standard", which
is not the case), it could separate all healthy people from
those who have the disease (i.e., people with BP values
that require treatment from those who do not). In such a
hypothetical case the blood pressure measurement would
be 100% sensitive and 100% specific, with no false-posi-
tive or false-negative results.
In reality, things are much different; there are two normal
distributions of blood pressure "test" results. One is for
individuals free of disease and one for individuals who
have the disease. Framing the reality in this way is still
misleading because in practice many patients may have
raised blood pressure levels (but are "disease free", insofar
as they may not need pharmacologic treatment – e.g.,
white coat hypertension) [29,30] and, many patients may
display apparently normal blood pressure values but, def-
initely need pharmacologic treatment (because of high
absolute risk for CVD, the presence of a compelling indi-
cation or of masked hypertension) [29,30].
In fact, there is an overlap of the two distributions and
that overlap is rather large; it predisposes to both over-
and underdiagnosis, i.e., false-positive and false-negative
results. The immediate consequence under the current cir-
cumstances of conventional office BP measurement is that
setting any test value (i.e., BP threshold) as cut-off point
to distinguish between "normal" and "abnormal", will
misclassify a great proportion of the patients falling into
the overlap area (Fig. 4) – a real uncertainty range exposing
to misdiagnosis (i.e., under- and overdiagnosis) [30].
As Fig. 4 illustrates, for our diagnostic "test" (the office BP
measurement) which does not behave as a "gold stand-
ard", there are four distinct alternatives [31]:
1. True negatives (TN) – subjects without the disease who
test negative (i.e., normal BP and no indication for blood
pressure lowering treatment).
2. True positives (TP) – subjects who have the disease and
test positive (i.e., sustained hypertension requiring phar-
macologic treatment).
3. False-negatives (FN) – subjects who have the disease
but test negative (i.e., normal BP, however, in need to get
pharmacologic treatment (e.g., masked hypertension).
4. False-positives (FP) – subjects who do not have the dis-
ease but test positive (i.e., subjects with high blood pres-
sure values but in no need for pharmacologic treatment
(e.g., white coat hypertension).
Fig. 4 also illustrates the dynamic complexity of what goes
on around the cut-off point selected. As mentioned in the
Illustration of the normality concept in a normal distribution Figure 3
Illustration of the normality concept in a normal distribution.
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first part of this paper, many national hypertension socie-
ties still maintain a cut-off point for blood pressure nor-
mality/abnormality by 160/95 mmHg [32]. For those
societies which decided to select 140/90 mmHg as cut-off
point, the switch from 160/95 to 140/90 mmHg has
meant a substantial change of several important diagnos-
tic parameters (including the prevalence of the condition)
[33].
Namely, the sensitivity of the test has increased, however,
with a simultaneous decrease in its specificity. The
number of TPs has increased as compared to the number
of FNs. Further, the move of the cut-off point to the left on
the BP curve has caused an increase in FPs as compared to
the FNs.
With other words, a high cut-of point on the BP curve
implies less false-positive results (and less overdiagnosis)
with the reverse occurring if the cut-off point is low.
Selection of "best cut-off point" can be enhanced by con-
structing a receiver operating characteristic (ROC) curve
(Fig. 5) [34]. Such a curve displays sensitivity on the X-axis
and the false positive error rate (1-specificity) on the Y-axis.
These two parameters can be computed for different
threshold values on the basis of points plotted on the
graph, as results of blood pressure measurements in
individuals with known health status (hypertension/no
hypertension).
A cut-off point set at 0 would mean a "test" (i.e., BP meas-
urement) with 100% sensitivity and ability to detect all
patients with genuine hypertension (i.e., sustained
Result alternatives by office BP measurement and the trade-off displayed by the sensitivity and specificity of the method as  related to the cut-off point selected (140/90 mmHg) Figure 4
Result alternatives by office BP measurement and the trade-off displayed by the sensitivity and specificity of the method as 
related to the cut-off point selected (140/90 mmHg).
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hypertension). However, all normal individuals (i.e.,
without hypertension) would screen positive, as reflected
by a 100% false-positive error rate (overdiagnosis). The
corresponding point would be placed in the right upper
corner of the graph.
In the other extreme, a hypothetical cut-off point of 350
mmHg, for example, would imply that virtually all
hypertensive patients were missed (underdiagnosis),
reflected by 0% sensitivity. This point would be placed in
the lower left corner of the graph.
Using a similar reasoning, the sensitivity and the false-
positive error rate can be computed for increasing thresh-
old values. Connecting the points plotted on the graph
would generate a ROC curve.
As the left upper corner represents a sensitivity of 100%
and 0% false-positive rate, the real best cut-off point is the
one lying closest to it.
Fig. 5 suggests that the 140/90 mmHg is, as a matter of
fact, the best cut-off point, a fact that should satisfy all
Receiver operating characteristic curve exploring the proper cut-off point for blood pressure measurement Figure 5
Receiver operating characteristic curve exploring the proper cut-off point for blood pressure measurement.
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those who are sceptical as to the value of this particular
threshold value. Obviously, its use does not preclude a
refined physician-patient dialog aiming at accounting for
the patients view regarding a particular antihypertensive
treatment, as Campbell and Murchie put it: "Appropriate
management of blood pressure should be guided by an
informed dialogue between patients and doctors and not
by blind pursuit of blood pressure targets"[35].
In fact, despite the drawbacks mentioned above, of an
arbitrarily selected office blood pressure cut-off point for
practical purposes, the office BP measurement as a
method as such, need not be entirely discarded.
On the contrary, there are three different instances in
which it may be used with certainty to decide whether to
treat or not to treat patients. The first two instances are
discernable from Fig. 4 and pertain to individuals without
any compelling indication (i.e.., diabetes mellitus or renal
dysfunction):
1). The great majority of individuals with office BP > 160/
95 mmHg are genuine hypertensives. They may have sus-
tained  essential hypertension (or a secondary form of
hypertension) [36]. Approximately 50% of myocardial
infarctions and one third of strokes are known to be asso-
ciated with BP > 160/95 mmHg. The presence of one or
several other risk factors further increase the certainty that
these patients need pharmacological treatment and care-
ful, long-term follow-up [5,37].
2). Likewise, the great majority of individuals with office
BP < 130/80 mmHg are likely to be free of hypertension
and/or the need for pharmacologic blood pressure
lowering treatment [38]. Regular health checks, for exam-
ple at two years intervals, are likely to capture propensity
toward increased risk, particularly among individuals
who, according to the current classification belong to the
high-normal  prehypertension category (130/85-139/89
mmHg).
In this context, it is worth re-emphasizing that blood pres-
sure values below the 140/90 mmHg cut-off point do not
confer total protection against a cardiovascular events.
Data from Framingham Study have shown that more than
one half (57%) of all heart attacks and almost one half of
all strokes in some population studies occur in persons
with normal office blood pressure [39-41].
3). The third instance pertains to patients with known dia-
betes mellitus and renal dysfunction. For these patients,
the office blood pressure measurement functions merely
as a quasi-"gold standard" test.
Fig. 6 illustrates the concept of two population distribu-
tions: one of diabetics without hypertension and another
of diabetics with associated hypertension. Given the wide-
spread consensus that patients with diabetes and associ-
ated hypertension should get pharmacological treatment
whenever BP > 130/80 mmHg [42,43], the two distribu-
tions do not appear to have any degree of overlap, with
the cut-off point of 130/80 mmHg discriminating well
between those supposed to be treated pharmacologically,
from those who are not.
A justifiable question that may arise is why a somewhat
lower cut-off point, i.e., 130/80 mmHg, can be considered
as more reliable than the 140/90 mmHg, given that office
BP measurement is likely to carry the same sort of prob-
lems in both cases.
The answer is pretty simple. An assumed overlap of the
two distributions (Fig. 6), leading to FP assessments
(overdiagnosis) and FNs (underdiagnosis), would cause
neither diagnosis nor management concerns. Namely,
patients with diabetes and associated hypertension need
aggressive antihypertensive treatment meant to lower BP
as much as possible [44-47]. Blood pressure measurement
errors around the cut-off point value of 130/80 mmHg
are, therefore, likely to have neither clinical nor prognos-
tic relevance, as long as the diabetes mellitus diagnosis is
certain.
Furthermore, Fig. 6 depicts a second cut-off point relevant
for the population of diabetics with associated hyperten-
sion: the 150/90 mmHg, which, according to current
guidelines is an indication for use of combination therapy
(two drugs from the start).
At closer scrutiny of the uncertainty range (≥ 130/85 to
<160/95 mmHg) (see Fig. 7) from its lower bound
upward, as assessed by office blood pressure measure-
ments, it appears to be a mix of populations consisting of:
• Subjects with prehypertension (high-normal BP ≥ 130/
85-139/89 mmHg)
• Patients with masked hypertension
• Subjects with white coat hypertension
• Patients with sustained hypertension
Fig. 8 attempts to depict the frequency distribution of the
aforementioned patient categories in a single, common
population distribution. It suggests that a great part of the
total population lies either in the in the uncertainty range
or under the area consisting of genuine hypertensive
patients (i.e., with sustained hypertension).Current Controlled Trials in Cardiovascular Medicine 2005, 6:5 http://cvm.controlled-trials.com/content/6/1/5
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A recent analysis of the worldwide global burden of
hypertension [48] indicated that 26.4% of the adult pop-
ulation in 2000 had hypertension and that 29.2% were
projected to have the condition by 2025. The hyperten-
sion prevalence is, however, considerably much higher in
economically developed countries as compared with
economically developing countries (37.3% versus 29.9%)
[48].
A multinational sample surveys carried out in six Euro-
pean countries, Canada and US, in the 1990s indicated
the age-adjusted prevalence of hypertension was 28% in
the North American countries and 44% in the European
countries [24].
About 59 million American adults (29%) fall into prehy-
pertension category (SBP 120-139 mmHg or DBP 80-89
mmHg) [49].
Extrapolating roughly from the above figures, the preva-
lence of hypertension in economically developed coun-
tries (37.3%) and the estimation of prehypertension in US
(29%) would add up to a 66.3% of the entire population
having a form of hypertension or prehypertension. This
average figure might be somewhat lower in America and
Canada but may reach 75% in the European countries.
Furthermore, epidemiological data [50] indicate that
approximately 25% of the community burden of BP-
related CVD is occurring among the population of hyper-
tensives with systolic BP ≥ 160 mmHg (representing only
approximately 5% of the total number of hypertensives).
About 33% of all BP-related CVD events are likely to occur
in the persons within normotensive BP range (<140
mmHg) while more than 66% of the same burden can be
attributed to the patient population with systolic BP ≥ 140
mmHg, i.e., belonging to the uncertainty range. Given that
the lower bound of the uncertainty range extends to 130/
85 mmHg (to include the high-normal prehypertension), it
might encompass as much as 80% of the total community
burden of BP-related CVD risk.
Prehypertension (PH)
The new JNC-7-hypertension category [49] was subject to
heavy criticism, primarily by European scientists who
argued that the new entity might have negative
psychological impact and generate a wave of more or less
unnecessary investigations in fairly healthy individuals.
Hypothetical, non-overlapping distributions of diabetics and diabetics with associated hypertension patients Figure 6
Hypothetical, non-overlapping distributions of diabetics and diabetics with associated hypertension patients.
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This is, certainly, not a strong argument even if it may con-
tain a grail of truth. Obviously, the sudden and
unexpected awareness that one, despite knowing him/
herself to be in good health, belong to a group of people
"at risk for heart disease", might trigger a more or less
uncomfortable feeling.
However, people with BP values in the range of 130-139/
85-89 mmHg, known to have high normal blood pressure
and labelled as being prehypertensives, are also known to
run a considerable higher risk for cardiovascular disease
than people with optimal (<120/80 mmHg) and with nor-
mal BP (120-129/80-84 mmHg) [49,51,52].
In a survey of 9845 Framingham Heart Study participants
over a 4-year period, 43% of the total of 1907 individuals
(19% of the original sample) who had high-normal blood
pressure at the initial screening have developed hyperten-
sion [53]. In contrast, only 6% of the subjects with optimal
blood pressure and 20% of those with normal  blood
pressure have developed hypertension [53]. Hypertension
incidence in all three categories increased with age, reach-
ing 37% among subjects with high-normal BP who were
35-64 years old and 50% among subjects aged 65 or older,
likewise, with high-normal  blood pressure at screening.
Worthwhile emphasizing, about 15% of the subjects with
high-normal blood pressure have progressed to stage II or
greater degree of hypertension over 4 years of follow-up.
Overall, compared with optimal blood pressure, high-nor-
mal blood pressure was associated with a 5- (age 35-64
years) to 12-fold (age 65 years or over) elevated odds of
hypertension on follow-up [53], justifying inclusion of
these subjects in the uncertainty area and thereby, the con-
sequent need for accurate diagnosis from the outset as
well as appropriate long-term management of these
individuals.
Masked Hypertension (MH)
As depicted by Fig. 7, individuals with MH fall into the
false negative area of the uncertainty range, suggesting that
the condition per se is perceived as normotension as
The uncertainty range and its mix of hypertension categories Figure 7
The uncertainty range and its mix of hypertension categories. Accurate diagnosis is only possible by ABPM.
Office BP < 115/75 120/80 130/85 140/90 160/95 > 179/109
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assessed by office blood pressure measurement. However,
MH is genuine hypertension, as assessed by daytime ABP
of >135/85 mmHg [54-58].
The reported prevalence rates of MH are 9% [59], 14%
[60], 23% [61] and 31% [62]. Individuals with masked
hypertension were shown to be similar with true hyper-
tensive patients in terms of left ventricular characteristics,
carotid artery wall thickness, and prevalence of discrete
atherosclerotic plaques [63] but to be different on several
demographic and lifestyle variables (greater proportion of
males, older, greater degree of alcohol consumption, past
smoking) [60,63].
Missed diagnosis of MH in these patients leaves them
untreated and at risk for long-term consequences of
hypertension.
Selenta et al. [60] have demonstrated that the BP values
falling in the borderline range (10 mmHg above and
below 140/90 mmHg) are particularly inaccurate. Most
participants presumed healthy in the 10 mmHg range
below 140/90 mmHg have hypertensive ABP, i.e., MH,
commonly missed by the office BP measurement. The
authors of the same article concluded that only those
office readings averaging 20 points above or below the
140/90 mmHg cut-off, represent safe diagnostic
information.
The high prevalence rates of MH and the high level of mis-
diagnosis rate by office BP measurement of the condition
calls for generalization of ABPM use in clinical practice,
for diagnosis and management purposes of this large
patient population.
Frequency distribution of hypertensive categories as parts of a common, normal distribution Figure 8
Frequency distribution of hypertensive categories as parts of a common, normal distribution.
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White coat hypertension (WCH)
Subjects with white coat hypertension have a normal aver-
age daytime blood pressure outside a medical setting
[64,65] but present with high BP in the medical environ-
ment [66,67]. By definition [68,69], white coat hyperten-
sion is diagnosed as such, if the conventional BP is
persistently  ≥ 140/90 mmHg and the average daytime
ambulatory BP is below 135/85 mmHg.
The prevalence rate of the WCH is reported to be in the
area of 15 to 35% of patients in whom hypertension is
diagnosed [70,71] and in nearly 30% of pregnant women
[72].
The use of a distinct cut-off point is important for diagnos-
tic and management purposes. It also distinguishes WCH
from the white coat effect, the latter being a quantitative
measure of the blood pressure rise in the presence of a
physician. This transient blood pressure rise has been
quantified by Mancia et al. [73] who demonstrated mean
value increases of 27 mmHg for both systolic and diastolic
pressure when measurement was done in the presence of
a physician. The white coat effect is commonly defined as
an office BP exceeding mean daytime ambulatory BP by at
least 20 mmHg systolic and/or 10 mmHg diastolic [74].
Such a large white coat effect has been found in as many
as 73% of treated hypertensive subjects and it may occur
more frequently in women than in men [75,76].
As illustrated by Fig. 7, both WCH as a distinct entity and
the white coat effect as a transitory BP rise, fall into the
false positive area of the uncertainty range, i.e., beyond the
140/90 mmHg cut-off point as assessed by office BP meas-
urement, and count thereby as overdiagnosis.
Indeed, the consequences of failing to identify white coat
hypertension are considerable. People may be penalized
for insurance and pension policies, and for employment
[77].
Long-term treatment may be prescribed unnecessarily
with all the risks derived from potential treatment-emer-
gent adverse reactions [78-80].
Given the seriousness as well as the high risk for such con-
sequences in the clinical practice, several hypertension
guidelines recommend use of ABPM for diagnosis of
WCH [81-83].
In 2001, the CMS in USA has selected "patients with sus-
pected WCH" as having indication for ABPM, with the use
of method itself being reimbursed [84].
Speculations on what clinical characteristics might suggest
the presence of WCH and thereby the need for ABPM, in
an attempt to preclude indiscriminate use of the method,
is certainly not justified anymore [85]. On the contrary,
current evidence argues in favour of ABPM use in all
patients with office blood pressure falling in the uncer-
tainty range (≥ 130/85 to <160/95 mmHg).
Once WCH has been diagnosed, ABPM should be
repeated at annual or biannual intervals [86] with the aim
to capture increased cardiovascular risk that would justify
initiation of drug treatment [87,88].
A holistic approach toward hypertension 
management
Fig. 7 suggests that ABPM should be used for further diag-
nostic work up of subjects whose office-measured BP val-
ues fall in the uncertainty range. Indeed, combining office
blood pressure (OBP) measurement values with ABPM
recording results (daytime normality cut-off point of 135/
85 mmHg) allows for discrimination among the follow-
ing diagnostic entities (see Fig. 9):
• Sustained Hypertension (SH) – (ABPM > 140/90 and
OBP ≥ 140/90)
• Masked Hypertension (MH) – (ABPM > 135/85 and
OBP < 140/90)
• White Coat Hypertension (WCH) – (ABPM < 135/85
and OBP ≥ 140/90)
• Prehypertension (high-normal BP) (PH) – (ABPM < 135/
85 and OBP 130/85-139/89)
The specific thresholds used for diagnostic discriminatory
purposes can also be used for management purposes. It is
widely agreed that poor control of hypertension is defined
by BP values > 140/90 mmHg [89] while good control, in
terms of ABPM, counts ≤ 135/85 mmHg [90-92]. Like-
wise, there is widespread agreement that patients with
clinic pressures of = 160/95 mmHg need drug treatment
[93].
The well-known, multifactorial inaccuracies imbedded in
the office blood pressure measurement and, in contrast to
that, the widespread agreement as to the superiority and
multi-purpose use of ABPM [94-102], as well as reports on
its cost-effectiveness [103] [104], make the method to
emerge as an additional alternative to the conventional
approach of hypertension management. While ABPM can,
on no account, be a replacement for the conventional
office blood pressure measurement, it is increasingly
obvious that its use is a sine qua non condition for accurate
diagnosis and management of subjects belonging to a
large segment of the general population displayingCurrent Controlled Trials in Cardiovascular Medicine 2005, 6:5 http://cvm.controlled-trials.com/content/6/1/5
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different forms of high blood pressure-related entities
(falling in the uncertainty range).
More recent studies provide evidence that the ABP testing
is generally well-accepted and tolerated by patients. A sur-
vey of 177 patients, who underwent ABPM in primary care
office setting in US over a 2.5 years period [103], showed
that 75% of them considered the 24-hour ABPM test as
worthwhile, with respect to the time and money incurred
by the investigation. Ninety per cent of the patients
thought that the results of the test were to provide useful
information for the physician's decision making on
appropriate therapy. Similar results were derived from a
qualitative study of ABPM in UK [71]. Both studies have
emphasized, however, the importance of the explanation
given by the physician to the patient as to the benefit of
undergoing ABPM testing, in order to minimize the per-
ception of discomfort related to the 24-hour recording.
Fig. 10 is an algorithmic approach to the management of
all subjects who display office blood pressure falling in
the uncertainty range (≥ 130/85 to < 160/95 mmHg). The
top part of the figure suggests that two different units are
involved in the management/investigation of such
patients, a usual GP or specialist office and a laboratory
specialised in ABPM recordings and results interpretation.
An initial assessment is commonly performed in the GP's
office where blood pressure is recorded, according to cur-
rent guidelines, by the physician or a trained nurse.
Patients whose average BP, derived from two
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measurements per visit, in two or several visits, lies in the
uncertainty range should be referred for 24-hour ABP
monitoring.
The result of the daytime ABPM assessed together with the
OBP generates a diagnostic conclusion matching one of
the following alternatives: SH/MH/WCH or PH (high-nor-
mal level).
Amazingly, the current conventional cut-off point of 140/
90 mmHg looses entirely its value for decision making, at
least in the initial stage assessment.
Indeed, as mentioned above, much information may be
lost when sensitivity and specificity are defined in relation
to a single cut-off point value of a continuous variable
(such as the BP). Instead, using a range, i.e., the interval
between two cut-off points (≥ 130/85 to <160/95 mmHg)
for further decision making, avoids the well-known diag-
nostic uncertainties.
The 140/90 cut-off point retains, however, its (arbitrary)
value in the next stage of ABPM investigation. The value of
the OBP, whether below or above the 140/90 mmHg
threshold is corroborated with the ABPM result for selec-
tion of one out of four different diagnostic alternatives:
sustained hypertension, masked hypertension, white coat
effect or high-normal prehypertension.
Once diagnosed, the patient returns to his/her physician
who remains in charge with the further management deci-
sion whatever the diagnosis might be (including lifestyle
changes, drug treatment, follow-up, etc.).
Obviously, diagnosis and management of patients who
have any form of symptomatic atherosclerotic vascular
disease including previous myocardial infarction, by pass
graft surgery, angina, stroke or transient ischaemic attack,
peripheral vascular disease or atherosclerotic renovascular
disease, need treatment of even mild hypertension (≥
140/90 mmHg) for secondary prevention. Likewise, patients
with target organ damage such as LVH, heart failure, pro-
teinuria or renal impairment need treatment of even very
mild hypertension.
Patients with type I and II diabetes mellitus and associated
mild hypertension (≥ 130/80 mmHg) generally have dia-
betic nephropathy and should be treated.
All the aforementioned compelling indications require drug
treatment for any level of raised blood pressure.
This translates in the need to apply the algorithm in Fig.
10 and perform formal absolute risk assessment only in
patients with uncomplicated hypertension (i.e., with BP
values falling in the uncertainty range ≥ 130/85 to <160/95
mmHg).
Conclusion
Accurate diagnosis and management of high blood pres-
sure is of paramount importance for the prevention of
long-term, cardiovascular, cerebrovascular and renal com-
plications. Aggressive attempts to identify and treat "high
blood pressure values" must be balanced carefully with
the risks of overdiagnosis and overtreatment in these
patients.
ABPM has a proven value not only as a research tool but
also as a valuable investigative method for a large segment
of the hypertensive population belonging to the uncer-
tainty range.
Practical management of these patients, once accurate
diagnosis has been established, should be based on abso-
lute cardiovascular disease risk and on a risk-communica-
tion dialog between the physician and patient as well as
on their mutual agreement regarding the specific treat-
ment to be initiated and the appropriate long-term
follow-up.
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